Fresh Issue vs Offer for Sale in an IPO: Where the Money Goes and Why It Matters

Open any Indian IPO prospectus and you’ll find the offer split into two pieces. That split, fresh issue vs offer for sale, decides who actually pockets your money. With a fresh issue, the company creates new shares and keeps the cash. With an offer for sale (OFS), existing shareholders like promoters or private equity funds sell shares they already hold, and the cash goes to them, not the company. So two IPOs of exactly the same size can mean very different things for the business you’re buying into.

In this guide we walk through how each piece works, what SEBI’s rules say about them, how to read the split in a red herring prospectus (RHP), and how to work out dilution on your own. Our running example is the live Paras Healthcare IPO. If primary markets are new to you, our pillar guide on IPO investing in India is a good place to start.

Fresh issue vs offer for sale: who gets paid

The SEBI FAQs on the ICDR Regulations describe an IPO as an unlisted company making a fresh issue of shares, or offering its existing shares for sale, or doing both, to the public for the first time. The General Information Document (GID) that comes with public issues says much the same: an IPO is an offer by an unlisted issuer, and it can include an offer for sale by any existing holder of its shares.

Side by side, the two look like this:

Prospectuses don’t sugar-coat this. The Paras Healthcare RHP says plainly that the company “will not receive any proceeds from the Offer for Sale” and that the selling shareholders “will receive the entire proceeds” from it, once their share of offer expenses is taken out.

An IPO’s headline size tells you how much money changes hands, not how much reaches the company. Only the fresh issue funds the business.

Inside a fresh issue

A fresh issue is primary capital. The company allots brand-new shares to successful bidders, so there are more shares outstanding after the IPO than before it. The money raised, less the company’s share of issue expenses, is the net proceeds. The RHP has to spell out the “objects of the offer”, which is just a formal way of saying what the money will be spent on: paying down debt, building a plant, opening stores, acquisitions, or general corporate purposes.

SEBI’s ICDR rules don’t let companies stay vague about it. As the Paras Healthcare RHP notes, the amount for general corporate purposes “shall not exceed 25% of the Gross Proceeds, in accordance with the SEBI ICDR Regulations.” That means at least three quarters of any fresh issue has to be linked to specific, disclosed uses.

New shares also mean dilution for existing owners. Investopedia explains, in the context of share sales after listing, that a dilutive offering adds to the total share count and can cut earnings per share (EPS), while a non-dilutive one adds no shares at all. Inside an IPO the logic is identical. The fresh issue is the dilutive bit; the OFS is the non-dilutive bit.

Inside an offer for sale

In an IPO’s OFS, named shareholders sell part or all of their existing stake to the public at the same offer price as the fresh issue. The GID defines allotment as the allotment of fresh issue shares plus the transfer of OFS shares to successful bidders, so whatever you get allotted can come from either pool. The business itself sees no cash from the OFS part.

Each selling shareholder is named in the RHP, along with how much they’re selling and their weighted average cost of acquisition (WACA) per share. The Paras Healthcare RHP puts all three on its cover page. That WACA number is one of the most useful things in the whole document. It tells you how much profit the sellers are booking at the IPO price.

A quick word on a common mix-up. “Offer for sale” is also the name of a separate route that already-listed companies use. The SEBI FAQ describes that OFS as existing shareholders, usually promoters or large investors, selling shares of a listed company to the public through the stock exchange. Same name, different mechanism. The exchange window has nothing to do with the OFS piece of an IPO.

Where SEBI treats the two pieces differently

A handful of ICDR rules apply one way to the fresh issue and another way to the OFS:

• Minimum subscription. The GID says the issuer must get a minimum subscription of 90% of the offer, leaving out any offer for sale. If the whole offer is an OFS, minimum subscription may not apply. And if the issuer falls short of that 90%, the GID says it must start unblocking bid amounts within four days of the issue closing.
• Who gets allotted first when demand is thin. Under-subscription? Then, per the GID, fresh issue shares are issued before any OFS shares are sold. Put differently, the company’s fundraising comes ahead of the sellers’ exit.
• Eligibility. On the profitability route, an IPO company needs net tangible assets of at least ₹3 crore in each of the preceding three full years, with no more than 50% held as monetary assets. The SEBI FAQ points out that this 50% monetary asset cap falls away if the public offer is entirely an offer for sale.
• Promoter lock-in tied to the fresh issue. According to the SEBI FAQ, promoters have to contribute at least 20% of post-issue capital, locked in for 1.5 years. That goes up to three years if most of the issue proceeds, excluding the OFS portion, will fund capital expenditure. The rest of the promoters’ pre-issue stake is locked in for six months, or one year in the capex case. Our guide to the IPO lock-in period goes deeper on these rules.

Look closely at the capex lock-in test. It measures proceeds “excluding the portion of offer for sale”. SEBI only cares how the fresh money gets used, since the OFS money never reaches the company anyway.

The Paras Healthcare IPO, split by split

Paras Healthcare, which operates hospitals under the Paras Health brand, opens its IPO on October 21, 2026, with a price band of ₹660 to ₹693 per share, BusinessLine (PTI) reports. It closes on October 23. Anchor bidding is on October 19, and listing is expected on October 28. Our Paras Healthcare IPO post has the full issue details.

The Paras Healthcare RHP filed with SEBI lays out the split:

That means ₹950 crore of the ₹1,450 crore issue, roughly 65.5% on our calculation, is OFS money walking out the door with the sellers. Just ₹500 crore, about 34.5%, is fresh capital. Fortune India reports that the company trimmed the IPO to ₹1,450 crore from the ₹1,800 crore proposed in its draft red herring prospectus, mostly by shrinking the OFS. Our explainer on the DRHP covers how terms can shift between the draft and the final filing.

What the fresh money is for

The RHP lists three objects for the fresh issue. ₹3,209 million (₹320.90 crore) goes to prepay or repay some of the company’s borrowings. ₹541 million (₹54.10 crore) is to be invested in its wholly owned subsidiary PMHPL, which runs the Srinagar hospital, so that it can repay its own borrowings. Whatever is left goes to general corporate purposes. Fortune India adds up the two debt items at ₹375 crore, or 75% of the fresh issue. For investors, the takeaway is simple: this new capital is mostly about fixing the balance sheet, not funding growth.

What the sellers paid for their shares

The cover page of the RHP shows the weighted average cost of acquisition per share, certified by the company’s chartered accountants. It’s ₹2.35 for Dr Nagar and ₹114.15 for Commelina. At ₹693, the top of the band, that’s about 295 times the promoter’s average cost and around 6.1 times Commelina’s, by our arithmetic. Neither figure tells you whether the IPO is fairly priced. What it does show is that the OFS is a profit-booking exit for both sellers.

The weighted average cost of acquisition is the quickest reality check in an RHP: it shows how far above their own entry price the sellers are asking you to buy.

Working out the dilution yourself

You don’t need anyone else’s estimate here. The RHP already has the numbers. Final share counts only firm up once the offer price is set, so read this as an upper-band estimate.

1. Shares before the issue. The RHP’s capital structure shows 100,986,187 equity shares of ₹1 face value before the offer.
2. New shares created. ₹500 crore divided by ₹693 gives roughly 72.15 lakh new shares (7,215,007, rounded down).
3. Shares after the issue. 100,986,187 + 7,215,007 = about 10.82 crore shares (108,201,194).
4. Dilution. 7,215,007 divided by 108,201,194 comes to about 6.7%. That’s the slice of the post-issue company held by the new fresh-issue shares, and every existing holder’s percentage stake shrinks by about that proportion.
5. Sanity check on market value. 108,201,194 shares times ₹693 is about ₹7,498 crore, which lines up with the roughly ₹7,498 crore post-issue market capitalisation Fortune India reported at the upper end of the band.

The OFS adds nothing to the share count. At ₹693, the ₹950 crore OFS means about 1.37 crore existing shares changing hands. Add the fresh shares and about 19.3% of post-issue share capital would be offered to the public, again on our upper-band maths.

What dilution does to EPS (hypothetical)

Take a made-up company with 10 crore shares and ₹100 crore of annual profit. Its EPS is ₹10.

• Suppose it sells 2 crore shares through an OFS only. The share count stays at 10 crore and EPS stays at ₹10. Ownership simply moves from the old holder to new investors.
• Now suppose it sells 2 crore new shares through a fresh issue. The share count goes to 12 crore. On the same ₹100 crore profit, EPS drops to about ₹8.33.
• If that fresh money pays off debt and saves, say, ₹12 crore of interest after tax, profit goes to ₹112 crore and EPS climbs back to about ₹9.33.

That’s the question that matters with any fresh issue. Will the money earn back more than the dilution costs existing holders? With an OFS, the company’s earning power doesn’t move at all.

Reading the split before you bid

Neither piece is good or bad by itself. A few practical checks go a long way:

• How big the OFS is. A large OFS usually means early investors are cashing out. In Paras Healthcare, Commelina, which Fortune India describes as an affiliate of Malaysian private equity firm Creador, is selling ₹650 crore. That isn’t a red flag on its own, but part of your money is funding an exit, not the business.
• Who’s selling. A financial investor selling after a long hold is routine. A promoter offloading a big chunk is worth a closer look at the post-issue promoter holding in the RHP.
• What the fresh money does. Paying down debt strengthens the balance sheet and can lift profit through lower interest. Capex can grow the business, but it takes time. A large general corporate purposes line gives you less to go on, which is exactly why SEBI caps it at 25% of gross proceeds.
• What the sellers paid. Compare the WACA with the price band. A wide gap doesn’t make an IPO overpriced, but it should nudge you to check valuation against listed peers instead of leaning on grey market chatter.
• How the price is set. Both pieces are sold at a single price found through book building. Our guide to the IPO cut off price explains how retail bids at that price work.

Questions readers often ask

Can I bid only for the fresh issue shares?

No. You put in one bid for the IPO at the offer price. Allotted shares come out of the combined offer, and there’s no separate application for the fresh issue or the OFS.

Does an OFS mean the promoter is on the way out?

Not always. Take Paras Healthcare: the promoter is selling up to ₹300 crore of shares and still stays the named promoter in the RHP. SEBI’s lock-in rules make promoters hold a minimum contribution of 20% of post-issue capital for a set period, so check the RHP’s post-issue shareholding table to see what they keep.

Why have an OFS at all?

SEBI’s definition of an IPO includes an unlisted company offering its existing shares for sale to the public, not only issuing new ones. The OFS lets promoters and early investors sell part of their stake at the price discovered through book building.

Can an IPO be 100% OFS?

Yes. Both the SEBI FAQ and the GID refer to offers made entirely through an offer for sale, and the GID notes minimum subscription may not apply then. An IPO like that raises no new money for the company.

Before you hit apply

The fresh issue vs offer for sale split shows you where the IPO money lands. Fresh issue cash goes to the company and dilutes existing holders. OFS cash goes to the sellers and leaves the share count untouched. In the Paras Healthcare IPO, about two thirds of the ₹1,450 crore issue is OFS, and the ₹500 crore fresh issue is mostly set aside for repaying debt. Whatever IPO you’re looking at, read the “Objects of the Offer” section, check who’s selling and at what cost, and run the dilution numbers yourself.

This article is for education only and is not investment advice. Paras Healthcare figures are taken from its RHP and the linked news reports; dilution, share counts and percentages are our own estimates at the upper end of the price band, and final figures will be in the prospectus. The EPS example is hypothetical. Always read the RHP of the specific issue and consult a SEBI-registered investment adviser before making investment decisions.